Christine E. Ryan, Inhye E. Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M. Parry, Miguel Alcoceba, Dinis P. Calado, Alberto Orfao, Anton W. Langerak, Hendrik Veelken, Petra Langerbeins, Deborah M. Stephens, Sameer A. Parikh, Carsten U. Niemann, Sandrine Roulland, Kostas Stamatopoulos, Susan L. Slager, Tait Shanafelt, Paolo Ghia, Jessica Okosun, Matthew S. Davids
{"title":"单克隆b细胞淋巴细胞增多症（MBL）的生物学、进展和临床管理的最新进展：拦截血癌研讨会委员会的共识报告","authors":"Christine E. Ryan, Inhye E. Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M. Parry, Miguel Alcoceba, Dinis P. Calado, Alberto Orfao, Anton W. Langerak, Hendrik Veelken, Petra Langerbeins, Deborah M. Stephens, Sameer A. Parikh, Carsten U. Niemann, Sandrine Roulland, Kostas Stamatopoulos, Susan L. Slager, Tait Shanafelt, Paolo Ghia, Jessica Okosun, Matthew S. Davids","doi":"10.1038/s41408-025-01341-6","DOIUrl":null,"url":null,"abstract":"<p>In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"35 1","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee\",\"authors\":\"Christine E. Ryan, Inhye E. Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M. Parry, Miguel Alcoceba, Dinis P. Calado, Alberto Orfao, Anton W. Langerak, Hendrik Veelken, Petra Langerbeins, Deborah M. Stephens, Sameer A. Parikh, Carsten U. Niemann, Sandrine Roulland, Kostas Stamatopoulos, Susan L. Slager, Tait Shanafelt, Paolo Ghia, Jessica Okosun, Matthew S. Davids\",\"doi\":\"10.1038/s41408-025-01341-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.</p>\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":11.6000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-025-01341-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-025-01341-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.
期刊介绍：
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
